With a static model-based approach to assess the correlation between the inhibitory potential of anti-TB drugs and the prognosis, they predicted a strong possibility of DDIs for these drugs interacting with other OCT1 substrate drugs in vivo on affecting anti-TB efficacy. The gene discussed is SLC22A1; the disease is tuberculosis.